4D Molecular Therapeutics amends bylaws to update advance notice procedures

4D Molecular Therapeutics, Inc.

Board amended and restated bylaws on November 16, 2023.
Amendments update advance notice procedures for business brought before a meeting.
Amendments update advance notice procedures for nominations of directors.
Full text of Amended and Restated Bylaws filed as Exhibit 3.1 with the 8-K.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

4D Molecular Therapeutics, Inc.: Amended and restated bylaws to update advance notice procedures for business brought before a meeting and for nominations of directors (effective 2023-11-16).

Change: bylaw amendment
Effective: 2023-11-16

Exact text from the filing

On November 16, 2023, the Board of Directors (the “Board”) of 4D Molecular Therapeutics, Inc. (the “Company”) amended and restated the Company’s current amended and restated bylaws (the “Amended and Restated Bylaws”).

View on SEC.gov

Browse all governance changes →

4D Molecular Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-282259

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.